Successful treatment of hairy cell leukemia variant with rituximab

S. Narat, J. Gandla, A. Dogan, Atul Mehta

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia. Unlike HCL, it is resistant to most conventional treatment. We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years. Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant. He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD20. There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission. This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.

Original languageEnglish (US)
Pages (from-to)1229-1232
Number of pages4
JournalLeukemia and Lymphoma
Volume46
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Hairy Cell Leukemia
Prolymphocytic Leukemia
Bone Marrow
Therapeutics
Lymphocytosis
Thrombocytopenia
B-Lymphocytes
Spleen
Monoclonal Antibodies
Rituximab
Biopsy
Population

Keywords

  • Hairy cell leukemia variant
  • Rituximab
  • Splenomegaly
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Successful treatment of hairy cell leukemia variant with rituximab. / Narat, S.; Gandla, J.; Dogan, A.; Mehta, Atul.

In: Leukemia and Lymphoma, Vol. 46, No. 8, 08.2005, p. 1229-1232.

Research output: Contribution to journalArticle

Narat, S. ; Gandla, J. ; Dogan, A. ; Mehta, Atul. / Successful treatment of hairy cell leukemia variant with rituximab. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 8. pp. 1229-1232.
@article{3e9e4e1005184dd4a930eb16fa51e3c5,
title = "Successful treatment of hairy cell leukemia variant with rituximab",
abstract = "Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia. Unlike HCL, it is resistant to most conventional treatment. We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years. Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant. He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD20. There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission. This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.",
keywords = "Hairy cell leukemia variant, Rituximab, Splenomegaly, Thrombocytopenia",
author = "S. Narat and J. Gandla and A. Dogan and Atul Mehta",
year = "2005",
month = "8",
doi = "10.1080/10428190500083433",
language = "English (US)",
volume = "46",
pages = "1229--1232",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Successful treatment of hairy cell leukemia variant with rituximab

AU - Narat, S.

AU - Gandla, J.

AU - Dogan, A.

AU - Mehta, Atul

PY - 2005/8

Y1 - 2005/8

N2 - Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia. Unlike HCL, it is resistant to most conventional treatment. We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years. Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant. He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD20. There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission. This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.

AB - Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia. Unlike HCL, it is resistant to most conventional treatment. We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years. Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant. He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD20. There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission. This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.

KW - Hairy cell leukemia variant

KW - Rituximab

KW - Splenomegaly

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=23144445811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23144445811&partnerID=8YFLogxK

U2 - 10.1080/10428190500083433

DO - 10.1080/10428190500083433

M3 - Article

C2 - 16085567

AN - SCOPUS:23144445811

VL - 46

SP - 1229

EP - 1232

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -